Home Europe European Commission wants to order 200 million doses of vaccine from BioNTech...

European Commission wants to order 200 million doses of vaccine from BioNTech and Pfizer | News from Germany about Germany | DW

54
0

The European Commission (EC) intends to buy 200 million doses of a possible coronavirus vaccine developed by the German firm BioNTech and the American concern Pfizer. In addition, sooner or later it’s deliberate to position an order for an additional 100 million doses of vaccine. Representatives of the EC and each pharmaceutical corporations introduced this on Wednesday, September 9. According to them, the primary negotiations on provides have been profitable.

Deliveries can start on the finish of 2020, as quickly because the related authorities approve the admission of the vaccine to the market. We are speaking about samples of the BNT162 vaccine, based mostly on mRNA (messenger RNA, or switch of an RNA fragment – the genetic code of the virus. – Ed.). If profitable, the vaccine will probably be distributed among the many nations of the European Union.







Phase 3 medical trials of a coronavirus vaccine

On September 7, BioNTech and Pfizer introduced the ultimate section of medical trials in Germany. To date, 25,000 volunteers have participated in medical trials at 120 analysis facilities around the globe, it’s estimated that by the top of the examine, their quantity will probably be 30,000.

“Large, managed Phase III trials are important to conclusively verify security and vaccine effectiveness“, – mentioned the co-founder of BioNTech Ugur Sahin (Ugur Sahin).

Around the world, pharmaceutical issues and biotech corporations are working to develop a vaccine for the coronavirus. In Germany, one other enterprise started to conduct medical trials earlier – the biotechnical firm CureVac from Tübingen.

Criticism of the Russian vaccine in opposition to the brand new coronavirus

The world’s first vaccine in opposition to the SARS-CoV-2 coronavirus “Sputnik-V” (Sputnik-V) was registered in Russia on August 11, even earlier than it handed the third section of trials, which includes testing the drug on a number of thousand volunteers.

In this regard, the Russian vaccine was criticized by many specialists and organizations, particularly the Association of Clinical Research Organizations (AOCI), which unites pharmaceutical corporations and individuals within the Russian medical analysis market.

See additionally:







LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.